Sean Maduck Sells 18,303 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 18,303 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $60.69, for a total transaction of $1,110,809.07. Following the sale, the insider now owns 85,622 shares in the company, valued at $5,196,399.18. This trade represents a 17.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Sean Maduck also recently made the following trade(s):

• On Thursday, January 2nd, Sean Maduck sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00.

Corcept Therapeutics Price Performance

NASDAQ:CORT opened at $55.49 on Thursday. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $75.00. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $60.20 and a 200 day simple moving average of $51.97. The stock has a market capitalization of $5.85 billion, a PE ratio of 44.04 and a beta of 0.58.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The firm had revenue of $181.89 million during the quarter, compared to the consensus estimate of $200.12 million. On average, research analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CORT shares. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and set a $115.00 price target on shares of Corcept Therapeutics in a research note on Thursday, February 27th. Piper Sandler raised their price target on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Finally, StockNews.com cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $99.75.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cache Advisors LLC bought a new position in Corcept Therapeutics during the fourth quarter worth $378,000. Public Employees Retirement System of Ohio raised its stake in Corcept Therapeutics by 269.9% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,859 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 2,086 shares in the last quarter. Vise Technologies Inc. acquired a new position in Corcept Therapeutics in the fourth quarter valued at about $204,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Corcept Therapeutics by 11.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 224,713 shares of the biotechnology company’s stock valued at $11,323,000 after purchasing an additional 22,361 shares in the last quarter. Finally, Teza Capital Management LLC acquired a new position in Corcept Therapeutics in the fourth quarter valued at about $212,000. 93.61% of the stock is owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.